Boston Scientific Corp banner

Boston Scientific Corp
NYSE:BSX

Watchlist Manager
Boston Scientific Corp Logo
Boston Scientific Corp
NYSE:BSX
Watchlist
Price: 59.035 USD -1.53%
Market Cap: $87.7B

EV/FCFF

26.4
Current
53%
Cheaper
vs 3-y average of 55.7

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
26.4
=
Enterprise Value
$101.2B
/
Free Cash Flow to Firm
$3.7B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
26.4
=
Enterprise Value
$101.2B
/
Free Cash Flow to Firm
$3.7B

Valuation Scenarios

Boston Scientific Corp is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (55.7), the stock would be worth $124.32 (111% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-13%
Maximum Upside
+111%
Average Upside
49%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 26.4 $59.04
0%
3-Year Average 55.7 $124.32
+111%
5-Year Average 55.7 $124.32
+111%
Industry Average 23 $51.43
-13%
Country Average 23.2 $51.85
-12%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
US
Boston Scientific Corp
NYSE:BSX
88.9B USD 26.4 24.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
167.2B USD 64.1 58
US
Abbott Laboratories
NYSE:ABT
161.2B USD 22.1 25.9
US
Stryker Corp
NYSE:SYK
125.8B USD 31.5 38.2
IE
Medtronic PLC
NYSE:MDT
106.4B USD 23.2 22.9
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD 32.9 43.3
DE
Siemens Healthineers AG
XETRA:SHL
40.1B EUR 21.2 18.9
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.8B USD 43.7 42.7
US
Becton Dickinson and Co
NYSE:BDX
42.8B USD 22.3 24.2
US
Resmed Inc
NYSE:RMD
32.3B USD 17.3 21.4
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
32.1B USD 24.4 15.2

Market Distribution

In line with most companies in the United States of America
Percentile
57th
Based on 8 393 companies
57th percentile
26.4
Low
0 — 15.4
Typical Range
15.4 — 35.1
High
35.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.4
Median 23.2
70th Percentile 35.1
Max 3 178 983.5

Boston Scientific Corp
Glance View

In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.

BSX Intrinsic Value
73.265 USD
Undervaluation 19%
Intrinsic Value
Price $59.035
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett